Our previous data demonstrated that the treatment of cultured cells of MPS IIIC patients bearing missense mutations with the competitive HGSNAT inhibitor (Ki = 0.28 mM) glucosamine, significantly increased the level of the residual N-acetyltransferase activity [24]. This evidence concerns the gene HGSNAT and mucopolysaccharidosis type 3C.